

## Procedural steps taken and scientific information after the authorisation

Ionsys

### MAJOR CHANGES<sup>1</sup>

| No       | Scope                                                                                                                                                                                                                                                                                          | Opinion issued on | Commission Decision Issued/ amended on | Product Information affected <sup>2</sup> | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|----------------------------------------|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A20/0013 | Article 20 Review                                                                                                                                                                                                                                                                              | 20/11/2008        | 16/01/2009                             |                                           | Please refer to the scientific discussion Ionsys-H-612-A20/0013-AR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0007  | Update of or change(s) to the pharmaceutical documentation                                                                                                                                                                                                                                     | 18/10/2007        | 21/11/2007                             | SPC, Labelling, PL                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0008  | To update the frequency of application site erythema in section 4.8 of the SPC and Section 4 of the PL from 'common' to 'very common'. Additionally, minor editorial changes have been made to the SPC and Labelling and the list of local representatives in section 6 of the PL was updated. | 20/09/2007        | 15/10/2007                             | SPC, Labelling, PL                        | <p>Further to the assessment of PSUR 1, the MAH was requested to specify the percentage of application site reactions that occur in the E-TRANS fentanyl group studies CAPSS 319, CAPSS 320 and Viscusi et al, as in study FEN-PPA-401 the occurrence of erythema is very common rather than common as it appears in the currently approved SPC.</p> <p>In their response the MAH discussed that the Application Site Reactions (ASR) were not assessed at scheduled time points after system removal. The different reporting, recording and evaluation methods between the trials contributed to the complexity of the assessment of ASR frequencies.</p> <p>The MAH amended the frequency of application site erythema from 'common' to 'very common' in Section 4.8 'Undesirable effects' of the SPC and Section 4 'Possible side effects' of the PL as requested by the CHMP on 21 June 2007.</p> |

<sup>1</sup> Major changes e.g. Type II variations, Annex II applications, Renewals and Annual Reassessments

<sup>2</sup> SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet)

**MINOR CHANGES<sup>3</sup>**

| No      | Scope                                                                                             | Product Information affected <sup>2</sup> | Date <sup>4</sup> |
|---------|---------------------------------------------------------------------------------------------------|-------------------------------------------|-------------------|
| IB/0010 | 33_Minor change in the manufacture of the finished product                                        |                                           | 05/08/2008        |
| IA/0012 | 22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer                  |                                           | 18/07/2008        |
| IA/0011 | 38_a_Change in test procedure of finished product - minor change to approved test procedure       |                                           | 18/07/2008        |
| IB/0009 | 42_a_01_Change in shelf-life of finished product - as packaged for sale                           | SPC                                       | 02/06/2008        |
| IA/0006 | 08_b_02_Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing         | Labelling, PL                             | 17/08/2007        |
| IB/0004 | 13_b_Change in test proc. for active substance - other changes (replacement/addition)             |                                           | 13/08/2007        |
| IB/0005 | 13_b_Change in test proc. for active substance - other changes (replacement/addition)             |                                           | 16/07/2007        |
| IA/0003 | 12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening of spec. |                                           | 26/06/2007        |
| IA/0002 | 12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening of spec. |                                           | 26/06/2007        |
| IA/0001 | 37_a_Change in the specification of the finished product - tightening of specification limits     |                                           | 26/06/2007        |

<sup>3</sup> Minor changes e.g. Type I variations and Notifications

<sup>4</sup> Date of entry into force of the change